Skip to main content
Livermore
Livermore
ZHEN

Armistice Capital, LLC

SEC CIK
0001601086
Latest filing
Aug 14, 2026

The latest 13F from Armistice Capital, LLC covers Q2 2026 (filed Aug 14, 2026): 323 long positions worth $3.61B. The top 10 holdings make up 27.4% of the portfolio, and the largest is Madrigal Pharmaceuticals, Inc. (MDGL) at 4.3%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
168
Est. +$375.6M
Added
70
Est. +$494.1M
Reduced
65
Est. −$683.8M
Sold out
96
Est. −$262.3M

Top 5 holdings

Share of this quarter's portfolio value

  1. MDGLMadrigal Pharmaceuticals, Inc.
    4.3%$154.6MHistory
  2. SUPNSupernus Pharmaceuticals, Inc.
    3.4%$123.1MHistory
  3. CYTKCytokinetics Inc
    2.8%$102.3MHistory
  4. INCYIncyte Corp
    2.8%$102.0MHistory
  5. NBIXNeurocrine Biosciences Inc
    2.5%$90.3MHistory

Share of portfolio

Top 5 holdings and the other 318 positions, by share of portfolio value

  1. MDGL4.3%
  2. SUPN3.4%
  3. CYTK2.8%
  4. INCY2.8%
  5. NBIX2.5%
  6. Other 318 positions84.2%

Biggest buys

New and added positions, by estimated amount bought

  1. CYTKCytokinetics Inc
    +$37.2MAddedHistory
  2. SUPNSupernus Pharmaceuticals, Inc.
    +$34.9MAddedHistory
  3. REGNRegeneron Pharmaceuticals, Inc.
    +$33.5MAddedHistory
  4. SNYSanofi
    +$32.6MAddedHistory
  5. WATWaters Corp
    +$28.1MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. CYTKCytokinetics Inc
    +1.17 pp1.7% → 2.8%History
  2. UNHUnitedHealth Group Inc
    +0.78 pp1.3% → 2.1%History
  3. INCYIncyte Corp
    +0.78 pp2.0% → 2.8%History
  4. SNYSanofi
    +0.78 pp0.5% → 1.3%History
  5. WATWaters Corp
    +0.78 pp0.0% → 0.8%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. TVTXTravere Therapeutics, Inc.
    −$188.9MReducedHistory
  2. PTCTPTC Therapeutics, Inc.
    −$81.8MReducedHistory
  3. IMVTImmunovant, Inc.
    −$70.5MReducedHistory
  4. DDOGDatadog, Inc.
    −$44.5MReducedHistory
  5. NBIXNeurocrine Biosciences Inc
    −$31.7MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. TVTXTravere Therapeutics, Inc.
    −2.33 pp4.8% → 2.5%History
  2. PTCTPTC Therapeutics, Inc.
    −2.25 pp4.7% → 2.4%History
  3. IMVTImmunovant, Inc.
    −1.07 pp2.9% → 1.9%History
  4. AVNSAvanos Medical, Inc.
    −0.93 pp0.9% → 0.0%History
  5. MDLNMedline Inc.
    −0.83 pp0.8% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$3.61B
+$585.9M (+19.3%) vs. prior quarter
Positions
323
+72 vs. prior quarter
Top 10 concentration
27.4%
Top 10 as share of value
Turnover
26.2%
Q2 2026, one quarter
Average holding period
10.7 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $4.30B (Q1 2023)

Q1 2021: $3.12BQ2 2021: $3.77BQ3 2021: $4.05BQ4 2021: $4.11BQ1 2022: $3.51BQ2 2022: $3.90BQ3 2022: $3.97BQ4 2022: $3.72BQ1 2023: $4.30BQ2 2023: $3.98BQ3 2023: $3.36BQ4 2023: $3.77BQ1 2024: $3.76BQ2 2024: $3.82BQ3 2024: $3.82BQ4 2024: $4.30BQ1 2025: $3.74BQ2 2025: $2.64BQ3 2025: $3.19BQ4 2025: $4.08BQ1 2026: $3.03BQ2 2026: $3.61B
Q1 2021Q2 2026
13F filings of Armistice Capital, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 2026323$3.61BMDGLSUPNCYTKvs. Q1 2026SEC
Q1 2026May 15, 2026251$3.03BTVTXPTCTMDGLvs. Q4 2025SEC
Q4 2025Feb 17, 2026357$4.08BPTCTMDGLIMVTvs. Q3 2025SEC
Q3 2025Nov 17, 2025318$3.19BPTCTTVTXSUPNvs. Q2 2025SEC
Q2 2025Aug 14, 2025200$2.64BPTCTSUPNTVTXvs. Q1 2025SEC
Q1 2025May 15, 2025220$3.74BPTCTSUPNTVTXvs. Q4 2024SEC
Q4 2024Feb 14, 2025227$4.30BPTCTSUPNTVTXvs. Q3 2024SEC
Q3 2024Nov 14, 2024254$3.82BPTCTSUPNINCYvs. Q2 2024SEC
Q2 2024Aug 14, 2024250$3.82BPTCTSUPNNBIXvs. Q1 2024SEC
Q1 2024May 15, 2024333$3.76BPTCTNBIXINCYvs. Q4 2023SEC
Q4 2023Feb 13, 2024291$3.77BPTCTNBIXSUPNvs. Q3 2023SEC
Q3 2023Nov 14, 2023250$3.36BSUPNPTCTNBIXvs. Q2 2023SEC
Q2 2023Aug 14, 2023218$3.98BNBIXSUPNMRTXvs. Q1 2023SEC
Q1 2023May 15, 2023223$4.30BNBIXTVTXSUPNvs. Q4 2022SEC
Q4 2022Feb 14, 2023191$3.72BMRTXSUPNTVTXvs. Q3 2022SEC
Q3 2022Nov 14, 2022195$3.97BINCYSUPNPTCTvs. Q2 2022SEC
Q2 2022Aug 15, 2022176$3.90BINCYMRTXSUPNvs. Q1 2022SEC
Q1 2022May 16, 2022139$3.51BTVTXINCYBIIBvs. Q4 2021SEC
Q4 2021Feb 14, 2022143$4.11BINCYBMYTVTXvs. Q3 2021SEC
Q3 2021Nov 15, 2021135$4.05BINCYBMYMRTXvs. Q2 2021SEC
Q2 2021Aug 16, 2021114$3.77BAVTXBIIBVRTXvs. Q1 2021SEC
Q1 2021May 17, 2021109$3.12BAVTXBMYMRTX–SEC

13D and 13G filings

Companies where Armistice Capital, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

66 companies, largest stake first.

Companies where Armistice Capital, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
ARDSAridis Pharmaceuticals, Inc.13G/A11.43%5.10M shares0.00 ppfrom 11.43%Feb 14, 20239 filingsAug 14, 2026SEC
CTORCitius Oncology, Inc.13G/A9.99%9.35M shares0.00 ppfrom 9.99%Nov 14, 20254 filingsAug 14, 2026SEC
QTEXQTREX Quantum Ltd.13G9.99%4.34M shares–Feb 14, 20243 filingsMay 15, 2026SEC
GNLXGENELUX Corp13G9.99%4.22M sharesNewNov 14, 20251 filingNov 14, 2025SEC
CALCCalciMedica, Inc.13G9.99%3.41M sharesNewAug 14, 20261 filingAug 14, 2026SEC
DWTXDogwood Therapeutics, Inc.13G/A9.99%3.38M shares0.00 ppfrom 9.99%May 15, 20262 filingsAug 14, 2026SEC
GLBSGlobus Maritime Ltd13G/A9.99%2.28M shares–Aug 14, 20251 filingAug 14, 2025SEC
INUVInuvo, Inc.13G9.99%1.65M sharesNewAug 14, 20261 filingAug 14, 2026SEC
CHGAChange Agents Corporation.13G9.99%1.60M shares0.00 ppfrom 9.99%May 15, 20262 filingsAug 14, 2026SEC
PWCMPowercompute, Inc.13G/A9.99%1.50M shares+2.72 ppfrom 7.27%Aug 14, 20253 filingsFeb 17, 2026SEC
CRISCuris Inc13G/A9.99%1.29M shares–Aug 14, 20251 filingAug 14, 2025SEC
CFRXCONTRAFECT Corp13G9.99%1.19M shares–Feb 14, 20233 filingsAug 14, 2025SEC
Bellicum Pharmaceuticals, IncCommon Stock13G9.99%1.08M shares–Feb 16, 20216 filingsAug 14, 2025SEC
DRMADermata Therapeutics, Inc.13G/A9.99%1.07M shares0.00 ppfrom 9.99%Feb 14, 20244 filingsMay 15, 2025SEC
FBLGFibroBiologics, Inc.13G9.99%739.0K sharesNewAug 14, 20261 filingAug 14, 2026SEC
QUCYQuantum Cyber N.V.13G/A9.99%723.1K shares–Aug 14, 20251 filingAug 14, 2025SEC
BCLIBrainstorm Cell Therapeutics Inc.13G9.99%717.5K shares+5.00 ppfrom 4.99%Nov 14, 20243 filingsMay 15, 2025SEC
CODXCo-Diagnostics, Inc.13G9.99%559.7K sharesNewAug 14, 20261 filingAug 14, 2026SEC
EDBLEdible Garden AG Inc13G9.99%544.3K shares+5.00 ppfrom 4.99%Nov 14, 20244 filingsFeb 17, 2026SEC
CYTOFAltamira Therapeutics Ltd.13G/A9.99%473.9K shares0.00 ppfrom 9.99%Nov 14, 20243 filingsMay 15, 2025SEC
IMNNImunon, Inc.13G/A9.99%450.3K shares0.00 ppfrom 9.99%Feb 17, 20263 filingsAug 14, 2026SEC
SNAXStryve Foods, Inc.13G9.99%439.4K sharesNewNov 14, 20251 filingNov 14, 2025SEC
GITSGlobal Interactive Technologies, Inc.13G9.99%407.8K sharesNewAug 14, 20261 filingAug 14, 2026SEC
ENVBEnveric Biosciences, Inc.13G9.99%405.1K shares–Feb 14, 20243 filingsAug 14, 2026SEC
SNAXStryve Foods, Inc.13G/A9.99%397.1K shares0.00 ppfrom 9.99%Feb 14, 20255 filingsAug 14, 2026SEC

Showing the 25 largest of 66 stakes.

Latest filings

903 filings on file made by Armistice Capital, LLC or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Armistice Capital, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
WLDSWearable Devices Ltd.Aug 14, 202610:30 AM ET13G/A4.99%167.5K shares−3.01 ppfrom 8.00%Below 5%Jun 30, 2026SEC
VYGRVoyager Therapeutics, Inc.Aug 14, 202610:30 AM ET13G/A5.58%3.44M shares−0.29 ppfrom 5.87%Jun 30, 2026SEC
VVOSVivos Therapeutics, Inc.Aug 14, 202610:29 AM ET13G/A4.99%729.8K shares−3.28 ppfrom 8.27%Below 5%Jun 30, 2026SEC
VSTMVerastem, Inc.Aug 14, 202610:29 AM ET13G/A7.76%7.02M shares+2.53 ppfrom 5.23%Jun 30, 2026SEC
VSEEVsee Health, Inc.Aug 14, 202610:29 AM ET13G/A7.33%4.08M shares−2.66 ppfrom 9.99%Jun 30, 2026SEC
TVTXTravere Therapeutics, Inc.Aug 14, 202610:28 AM ET13G/A1.67%1.57M shares−3.60 ppfrom 5.27%Below 5%Jun 30, 2026SEC
TRVNTrevena IncAug 14, 202610:27 AM ET13G9.91%95.0K shares–Jun 30, 2026SEC
TNONTenon Medical, Inc.Aug 14, 202610:27 AM ET13G9.99%54.6K sharesNewJun 30, 2026SEC
TMCITreace Medical Concepts, Inc.Aug 14, 202610:27 AM ET13G/A9.79%6.36M shares−0.06 ppfrom 9.85%Jun 30, 2026SEC
SNAXStryve Foods, Inc.Aug 14, 202610:26 AM ET13G/A9.99%397.1K shares0.00 ppfrom 9.99%Jun 30, 2026SEC
SGMOQSangamo Therapeutics, IncAug 14, 202610:26 AM ET13G/A9.38%38.9M shares−0.37 ppfrom 9.75%Jun 30, 2026SEC
RPIDRapid Micro Biosystems, Inc.Aug 14, 202610:25 AM ET13G7.29%3.33M sharesNewJun 30, 2026SEC
RKDAArcadia Biosciences, Inc.Aug 14, 202610:25 AM ET13G/A9.99%267.4K shares+2.24 ppfrom 7.75%Jun 30, 2026SEC
RIGLRigel Pharmaceuticals IncAug 14, 202610:24 AM ET13G/A8.95%1.67M shares+2.02 ppfrom 6.93%Jun 30, 2026SEC
REVBRevelation Biosciences, Inc.Aug 14, 202610:24 AM ET13G/A4.99%209.2K shares−2.81 ppfrom 7.80%Below 5%Jun 30, 2026SEC
PWCMPowercompute, Inc.Aug 14, 202610:23 AM ET13G/A9.99%83.8K shares0.00 ppfrom 9.99%Jun 30, 2026SEC
OLBOlb Group, Inc.Aug 14, 202610:23 AM ET13G/A8.58%1.53M shares−1.41 ppfrom 9.99%Jun 30, 2026SEC
OFIXOrthofix Medical Inc.Aug 14, 202610:23 AM ET13G/A8.01%3.26M shares+1.28 ppfrom 6.73%Jun 30, 2026SEC
NUWENuwellis, Inc.Aug 14, 202610:22 AM ET13G/A4.99%73.4K shares−2.12 ppfrom 7.11%Below 5%Jun 30, 2026SEC
MGNXMacrogenics IncAug 14, 202610:22 AM ET13G/A7.88%5.01M shares−1.58 ppfrom 9.46%Jun 30, 2026SEC